The Europe Plant-based API Market would witness market growth of 5.6% CAGR during the forecast period (2023-2030).
The development of genomics as well as biotechnology, has made it possible to identify and isolate particular genes that are responsible for the synthesis of active chemicals in plants. As a result, new plant types have been created that produce greater amounts of active chemicals, which may then be used to create new plant-based APIs. This has also drawn the attention of numerous small and large businesses, who are investing in this field and helping the market to flourish.
Discovering intriguing prospective treatments has been made possible by recent developments in the creation of genetic & genomic high-throughput systems for use in gene regulation and expression studies. Other helpful techniques recently reached the forefront of genomic research, including next-generation DNA & RNA sequencing, micro-droplet digital PCR, and microarray-based CGH. Additionally, over half of all medications are made from natural sources, which means that the APIs are made mostly from plants grown as crops.
The "Healthier Together EU Non-Communicable Diseases Initiative" runs from 2022 to 2027 and seeks to assist EU nations in identifying and implementing efficient policies and measures to lessen the burden of major NCDs and enhance the health and well-being of their citizens. It consists of a horizontal strand on health determinants, emphasizing population-level health promotion as well as the prevention of NCDs (to complement the initiatives of Europe's Beating Cancer Plan). The Initiative also consists of four strands on disease-specific topics, including diabetes, cardiovascular diseases, chronic respiratory diseases, mental health issues, and neurological disorders. The Initiative will assist nations in achieving Target 3.4 of the United Nations Sustainable Development Goals, which calls for a reduction in premature mortality from NCDs of one-third by 2030 as well as the promotion of mental health and overall well-being.
The Germany market dominated the Europe Plant-based API Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $2,781.9 million by 2030. The UK market is anticipated to grow at a CAGR of 4.7% during (2023 - 2030). Additionally, The France market would exhibit a CAGR of 6.4% during (2023 - 2030).
Based on End-use, the market is segmented into Pharmaceuticals, Nutraceuticals, and Herbal Based Industries & Others. Based on Molecule Type, the market is segmented into Alkaloids, Anthocyanin, Flavonoids, Phenolic Acids, Lignin & Stilbenes, Terpenoids, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Worldwide Plant-based API Market is Projected to reach USD 42.6 Billion by 2030, at a CAGR of 5.8%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include BASF SE, Evonik Industries AG (RAG-Stiftung), Cargill, Incorporated, Roquette Freres SA, Arboris, LLC, Centroflora Group, Kothari Phytochemicals & Industries Ltd., Brains Bioceutical Corp., Indo Phytochem Pharmaceuticals and HimPharm.
By End-use
By Molecule Type
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
